Complement-Targeting Agent ANX005 Demonstrates Therapeutic Efficacy in Phase 3 Study of Guillain-Barré Syndrome

Presented at the 2025 AAN Annual Meeting, findings from a phase 3 study showed that a single 30 mg/kg dose of ANX005 significantly improved health outcomes in Guillain-Barré syndrome, with benefits seen as early as week 1 and sustained over 6 months.:

Source: Neurology Read More